This post-hoc analysis used a combined cohort of 509 patients with RET-mutated advanced or metastatic medullary thyroid cancer who had received selpercatinib in the two trials. Hadoux reported that ...
With over 200 types of cancer, it can be overwhelming to know which symptoms to look out for. Yet, one less obvious sign of cancer can appear on your sheets and pillows during the night ...
Cabozantinib is the active ingredient in two of Exelixis' three approved drugs (Cabometyx and Cometriq) and its strongest US patent covering cabozantinib’s composition of matter expires in 2030.